BKI-1748, which targets <i>Toxoplasma gondii</i> CDPK1 and MAPKL-1 protein kinases, has demonstrated an excellent safety profile and efficacy when administered repeatedly to pregnant sheep, starting at 2 and 7 days after challenge.<h4>Methods</h4>In this study, treatment was initiated at day 14 post-infection (p.i.), following <i>T. The gene discussed is WEE1; the disease is infection.